| 3.615 0.055 (1.54%) | 12-08 12:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.52  |
1-year : | 6.54 |
| Resists | First : | 4.73 |
Second : | 5.59 |
| Pivot price | 3.57 |
|||
| Supports | First : | 3.32 | Second : | 2.77 |
| MAs | MA(5) : | 3.55  |
MA(20) : | 3.64 |
| MA(100) : | 4.62 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 54.9 |
D(3) : | 43.2 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 6.51 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABCL ] has closed below upper band by 35.1%. Bollinger Bands are 73.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.69 - 3.71 | 3.71 - 3.73 |
| Low: | 3.48 - 3.5 | 3.5 - 3.53 |
| Close: | 3.53 - 3.56 | 3.56 - 3.6 |
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Fri, 05 Dec 2025
AbCellera Biologics’ Earnings Call: Key Insights - MSN
Fri, 05 Dec 2025
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Fri, 05 Dec 2025
AbCellera Biologics (NASDAQ:ABCL) Nasdaq Today Biotech Pioneer - Kalkine Media
Thu, 04 Dec 2025
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results - Yahoo Finance
Tue, 25 Nov 2025
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss - Yahoo Finance
Tue, 18 Nov 2025
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 299 (M) |
| Shares Float | 203 (M) |
| Held by Insiders | 22.9 (%) |
| Held by Institutions | 37.6 (%) |
| Shares Short | 54,440 (K) |
| Shares Short P.Month | 53,200 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.25 |
| Profit Margin | 0 % |
| Operating Margin | -851.8 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -16.9 % |
| Qtrly Rev. Growth | 37.5 % |
| Gross Profit (p.s.) | -0.5 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -105 (M) |
| Levered Free Cash Flow | -241 (M) |
| PE Ratio | -6.36 |
| PEG Ratio | 0 |
| Price to Book value | 1.11 |
| Price to Sales | 30.71 |
| Price to Cash Flow | -10.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|